A variety of factors, such as low COVID-19 vaccination rates and Americans’ general poor health, is behind the life expectancy drop, experts say.
Author: Karen Weintraub, USA TODAY
Pot for pain relief? What cannabis can (and can’t) do for chronic pain.
A growing, but still incomplete body of research suggests the cannabis plant, the source of marijuana, can help fight some kinds of pain.
COVID-19 is about to explode in China. What that could mean for the United States.
Experts are predicting COVID cases in China will explode after the country ended its strict zero-COVID policy. Here’s how the US may be affected.
As COVID cases rise, White House announces more prevention efforts, including free tests
More free at-home COVID tests are part of the White House’s plan to combat rising cases this winter season.
Pain relief beyond pills? How drug alternatives are making a difference.
Doctors are increasingly looking to alternative ways to address pain, through exercise, physical therapy, yoga, meditation, massage and acupuncture.
America has a pain problem. How can we find relief?
To better understand America’s pain problem and what to do about it, USA TODAY spoke with more than 50 pain experts and people with chronic pain.
NFL players age faster than the rest of us. Harvard is researching what can be done.
A Harvard study finds NFL players age a decade faster than the general population and are suffering young from arthritis and high blood pressure.
Weight loss treatment is on the verge of transformation. It’s not there yet. Here’s why.
New medicines like Wegovy promise dramatic weight loss, but there’s a long way to go to make anti-obesity drugs accessible to those who need them.
Where did mpox go? Here’s what brought down cases of disease formerly known as monkeypox.
Cases of the disease formerly known as monkeypox are down as the Biden administration declares an end to the public health emergency.
Thousands of babies and children are hospitalized by RSV every year. Why that could soon change.
Six drug companies are now developing RSV vaccines or antibodies, suggesting this year could be the last without adequate tools to fight the virus.